January 8, 2024 08:14 AM ESTUpdated 10:15 AM
Deals
Pharma

J&J makes $2B push in­to AD­Cs with Am­brx buy­out in on­col­o­gy deal spree: #JPM24

Kyle LaHucik

Senior Reporter

SAN FRAN­CIS­CO — John­son & John­son is adding to Big Phar­ma’s love for an­ti­body-drug con­ju­gates with a $2 bil­lion cash deal to swoop up Am­brx Bio­phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Rhythm re­ceives ex­pand­ed ap­proval for ge­net­ic obe­si­ty drug

A service from the Financial Times